Table 1 |
|
|
E. coli vector vaccines |
|
| Name |
Plamid(s) |
|
|
|
| Invasive E. coli |
pGB2Ω-inv-hly |
| E. coli gfp |
pMC221 |
| E. coli gfp+inv |
pMC221, pGB2Ω-inv-hly |
| E. coli gfp+inv+IL12 |
pMC221, pGB2Ω-inv-hly, pORF-mIL12 |
| E. coli inv+IL12 |
pGB2Ω-inv-hly, pORF-mIL12 |
| Bioluminescent non-invasive E. coli |
pXen13™ |
| Bioluminescent invasive E. coli |
pXen13™, pGB2Ω-inv-hly |
| E. coli EYFP |
pEYFP-N1 |
| E. coli inv EYFP |
pEYFP-N1, pGB2Ω-inv-hly |
| E. coli inv B7a |
pGB2Ω-inv-hly, pDEST17-BmeII1097 |
|
aAll E. coli used in these studies were DH5a™ except E. coli inv B7 which is strain BL21-AI™. | |
Harms et al. Journal of Immune Based Therapies and Vaccines 2009 7:1 doi:10.1186/1476-8518-7-1 |
|